Home > Selected Past Studies

SELECTED PAST STUDIES - All Cancers - Bladder - Kidney - Prostate Cancers

Study

Disease

type & number of samples

Specific Requirements

associated data required

PT-1

Prostate Cancer

FFPE Blocks

Retrospective

More than 150 subjects

5 groups:

  • PrCa patients without recurrence for a minimum of 5 years and who underwent radical prostatectomy and who didn’t receive adjuvant therapy
  • PrCa patients with recurrence (within 3 years) and hormone refractory
  • PrCa patients with recurrence (within 3 years) and hormone sensitive.
  • PrCa patients who underwent transurethral resection of the prostate
  • PrCa patients with metastasis. Hormone refractory
  • Caucasian patients only
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History and medical out-come
  • Date of diagnosis
  • PSA at diagnosis
  • PSA after RPE
  • Date of any PSA increase

PT-2

Prostate Cancer

FFPE Blocks

Retrospective

More than 20 subjects Advanced Stage:

  • > or equal to T2 if Gleason score is 8-10
  • > or equal to T3 if Gleason score is > or equal to 7
  • 2 prostate tissue blocks per subject:
    • Primary tumor and matched metastatic sites
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)

PT-3

Prostate Cancer

Freshly Resected Tumor Material

Prospective

More than 10 subjects

  • Metastatic castrate-resistant PrCa (CRPC)
  • Sample size: 2 g
  • Samples must be received fresh within 24 hour of resection
  • Age, Ethnicity
  • Sample collection date
  • Tumor Grade and Stage
  • Treatment history

PT-4

Prostate Cancer

Plasma and Tumor Biopsy Samples

Retrospective

More than 120 subjects

3 groups:

  • PrCa patients: positive biopsy
  • Patients: negative biopsy
  • Healthy male controls: only plasma samples
  • Age-matched groups
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Gleason score
  • PSA value

PT-5

Prostate Cancer and Benign Prostate Hyperplasia

Serum

Retrospective

More than 400 subjects

2 groups:

  • Submitted to prostate biopsy and diagnosed with PrCa
  • Submitted to prostate biopsy and diagnosed with Benign Prostate Hyperplasia
  • PSA between 2-10 ng/ml
  • No prior biopsy within 5 years
  • No prior prostate surgery
  • Negative (non-suspicious) Digital Rectal Exam (DRE)
  • Blood samples taken before prostate biopsy
  • Samples stored at -80°C
  • No Hemolytic samples
  • No Samples with multiple freeze thaw cycles
  • Demographic, diagnostic and medical data
  • Sample collection date
  • PSA value
  • Diagnosis at biopsy
  • Positive prostate biopsy: Biopsy Gleason grade

PT-6

Castration-Resistant Prostate Cancer

Whole Blood

Prospective

More than 30 subjects

  • PSA level > 0.2 ng/ml and rising that is documented
  • Blood samples collected in specific RNA Tubes
  • Demographic data
  • Treatment History and medical out-come
  • Treatment history
  • Radiographic progression to confirm CRPC
  • Gleason Score
  • PSA velocity

PT-7

Prostate Cancer

Urine

Prospective

More than 18 subjects

  • Subjects with suspected PrCa (on the basis of abnormal PSA, urinary symptoms, family history of PrCa)
  • Untreated subjects only
  • No Digital Rectal Exam performed within the last 4 hours preceding specimen collection
  • Samples stored at -80°C
  • Age, ethnicity
  • Date of diagnosis
  • Data confirming diagnosis
  • PSA value

BL-1

Urothelial Cell Carcinoma of the Bladder

Fresh Frozen Tissue

Retrospective

More than 150 subjects

6 groups:

  • Ta low grade tumors
  • Ta high grade tumors
  • T1 high grade tumors
  • T2 tumors
  • T3 tumors
  • T4 tumors
  • Minimum of 20 mg of tiissue
  • Demographic, diagnostic and medical data
  • smoking status
  • Clinical history
  • Stage
  • Treatment History and medical out-come

BL-2

Urothelial Cell Carcinoma of the Bladder

Tissue Micro-Arrays

Retrospective

More than 200 subjects

  • Transitional cell carcinomas of the bladder
  • Including Papillary carcinoma, Papillary urothelial neoplasms and Insitu carcinoma
  • Caucasian patients only
  • Diagnosis biopsy or post-treatment biopsy
  • Surgery (partial or radical cystectomy)
  • Primary tumors or metastases
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History (Surgery, Chemotherapy, Biological therapy, Radiation therapy)
  • Medical out-come (2 years)

BL-3

Urothelial Cell Carcinoma of the Bladder

Peripheral Blood Mononuclear Cells

Prospective

More than 25 subjects

  • Advanced stage/higher grade
  • Patients with invasive tumors only
  • Several vials per subject
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History
  • HLA-typing

BL-4

Urothelial Cell Carcinoma of the Bladder

FFPE Blocks

Retrospective

More than 40 subjects:

2 Groups:

  • Invasive cases
  • Non-invasive cases (T1, Ta or Tcis)
  • FFPE blocks must allow the cutting of > 50 sections
  • Demographic, diagnostic and medical data
  • Stage (TNM, grade)
  • Treatment History

BL-5

Urothelial Cell Carcinoma of the Bladder

Freshly Resected Tumor Material

Prospective

More than 10 subjects

2 groups:

  • Transitional cell carcinoma
  • Epithelial Bladder Cancer
  • Samples must be received fresh within 24 hour of resection
  • Age, Gender, Ethnicity
  • Tumor Grade and Stage
  • Treatment history (if available)
  • Sample collection date

BL-6

Urothelial Cell Carcinoma of the Bladder

FFPE Blocks

Retrospective

More than 20 subjects

  • Stage III or IV, metastatic or surgically unresectable urothelial carcinoma
  • Primary tumors only
  • Any grade
  • Tissue Samples fixed in 10% Neutral Buffered Formalin (NBF)
  • FFPE blocks should allow the cutting of >50 sections
  • Demographic, diagnostic data
  • Stage (TNM, grade)
  • Sample collection date
  • Histological or cytological evidence of metastatic or surgically unresectalable transitional cell carcinoma

BL-7

Urothelial Cell Carcinoma

FFPE Blocks

Retrospective

More than 160 subjects 3 groups:

  • Non-invasive (stage T1, Ta, Tis)
  • Invasive (stage T2 or higher)
  • Stage III or IV, metastatic/unresectable
  • Diagnosed with Urothelial Cell Carcinoma
  • Age, Gender, Ethnicity
  • Sample collection date
  • Pathological diagnosis
  • Medical history